Literature DB >> 19117829

Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target.

Hai Hu1, Yuliang Ran, Yushan Zhang, Zhuan Zhou, Simon J Harris, Long Yu, Lixin Sun, Jian Pan, Jun Liu, Jinning Lou, Zhihua Yang.   

Abstract

Angiogenesis is critical for cancer development and metastasis. Here we have employed a functional antibody library-based proteomic screen to identify proteins that participate in and might be used as therapeutic targets for tumor-related angiogenesis. Mice were immunized with human esophageal cancer endothelial cells (HECEC). The antibody library was established with the mouse spleen cells the serum of which had most anti-angiogenic effect. Monoclonal antibodies were subjected to an immunoreactive and functional screen and monoclonal antibodies that reacted strongly with cell surface antigens of HECECs and influenced their behavior were selected. Antigens that recognized by the antibodies were obtained by immunoprecipitation and then identified by mass spectrometry analysis. Migration-stimulating factor (MSF), the antigen of 1D2 antibody was identified using this approach. Further studies demonstrated that the 1D2 antibody suppressed MSF-effected migration and adhesion of HECECs on fibronectin matrix. Biodistribution assay showed that MSF targeting antibody 1D2 could specifically home to the xenograft with humanized blood vessel. Targeting treatment with 1D2 antibody significantly suppressed tumor growth through inhibition of human tumor-related angiogenesis. These results indicate that the functional antibody library-based proteomic screen can successfully identify proteins that involved in tumor-related angiogenesis and MSF may be a target for the anti-angiogenic treatment of the esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19117829      PMCID: PMC2667360          DOI: 10.1074/mcp.M800331-MCP200

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  42 in total

1.  Genes expressed in human tumor endothelium.

Authors:  B St Croix; C Rago; V Velculescu; G Traverso; K E Romans; E Montgomery; A Lal; G J Riggins; C Lengauer; B Vogelstein; K W Kinzler
Journal:  Science       Date:  2000-08-18       Impact factor: 47.728

2.  Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: a pathway to overcome cell barriers to drug and gene delivery.

Authors:  Deirdre P McIntosh; Xiang-Yang Tan; Phil Oh; Jan E Schnitzer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

Review 3.  Fibronectin at a glance.

Authors:  Roumen Pankov; Kenneth M Yamada
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

Review 4.  The role of angiogenesis in prostate and other urologic cancers: a review.

Authors:  J I Izawa; C P Dinney
Journal:  CMAJ       Date:  2001-03-06       Impact factor: 8.262

Review 5.  VEGF-VEGF receptor complexes as markers of tumor vascular endothelium.

Authors:  R A Brekken; P E Thorpe
Journal:  J Control Release       Date:  2001-07-06       Impact factor: 9.776

6.  Targeting the prostate for destruction through a vascular address.

Authors:  Wadih Arap; Wolfgang Haedicke; Michele Bernasconi; Renate Kain; Daniel Rajotte; Stanislaw Krajewski; H Michael Ellerby; Dale E Bredesen; Renata Pasqualini; Erkki Ruoslahti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

7.  Prostaglandin E(1) protects human liver sinusoidal endothelial cell from apoptosis induced by hypoxia reoxygenation.

Authors:  Hong Yang; Pietro Majno; Philippe Morel; Christian Toso; Fréderic Triponez; José Oberholzer; Gilles Mentha; Jinning Lou
Journal:  Microvasc Res       Date:  2002-07       Impact factor: 3.514

Review 8.  Monoclonal antibody therapy for cancer.

Authors:  Margaret von Mehren; Gregory P Adams; Louis M Weiner
Journal:  Annu Rev Med       Date:  2001-12-03       Impact factor: 13.739

9.  The expression of migration stimulating factor, a potent oncofetal cytokine, is uniquely controlled by 3'-untranslated region-dependent nuclear sequestration of its precursor messenger RNA.

Authors:  Richard A Kay; Ian R Ellis; Sarah J Jones; Stéphane Perrier; Margaret M Florence; Ana M Schor; Seth L Schor
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

Review 10.  Phenotypic and genetic alterations in mammary stroma: implications for tumour progression.

Authors:  S L Schor; A M Schor
Journal:  Breast Cancer Res       Date:  2001-09-06       Impact factor: 6.466

View more
  4 in total

Review 1.  Tumor angiogenesis: molecular pathways and therapeutic targets.

Authors:  Sara M Weis; David A Cheresh
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

2.  Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 Binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer.

Authors:  Lichao Sun; Lizhao Chen; Lixin Sun; Jian Pan; Long Yu; LuLu Han; Zhihua Yang; Yuanming Luo; Yuliang Ran
Journal:  Mol Cell Proteomics       Date:  2012-11-26       Impact factor: 5.911

Review 3.  Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers.

Authors:  Björn L D M Brücher; Yan Li; Philipp Schnabel; Martin Daumer; Timothy J Wallace; Rainer Kube; Bruno Zilberstein; Scott Steele; Jan L A Voskuil; Ijaz S Jamall
Journal:  Clin Transl Med       Date:  2016-04-06

4.  Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages.

Authors:  Akihiro Maeda; Elisabeth Digifico; Fernando T Andon; Alberto Mantovani; Paola Allavena
Journal:  Eur J Immunol       Date:  2019-02-28       Impact factor: 5.532

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.